Table 5 Interaction between brain metastasis and afatinib starting dose in PFS. The interaction effect of brain metastasis and starting dose of afatinib (40 mg vs 30 mg OD) in PFS of patients shown in a multivariable model
From: Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases
No. of events / patients | Hazard ratio (95% CI) | p-value | |
|---|---|---|---|
Brain metastasis; starting dose | 60 / 119 | ||
Brain mets; 40 mg | 1 | ||
Brain mets; 30 mg | 3.73 (1.45, 9.61) | 0.006 | |
No brain mets; 40 mg | 1.29 (0.57, 2.96) | 0.542 | |
No brain mets; 30 mg | 1.21 (0.45, 3.23) | 0.711 | |
p-value of brain mets-starting dose interaction: | 0.020 | ||
Amongst never smokers with exon 19 deletion or L858R mutation: | |||
Brain metastasis; starting dose | 37 / 84 | ||
Brain mets; 40 mg | 1 | ||
Brain mets; 30 mg | 5.23 (1.42, 19.28) | 0.013 | |
No brain mets; 40 mg | 1.67 (0.57, 4.87) | 0.345 | |
No brain mets; 30 mg | 1.10 (0.29, 4.20) | 0.884 | |
p-value of brain mets-starting dose interaction: | 0.011 | ||